# FRUZAQLA® (fruquintinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/fruquintinib

> The FDA approved FRUZAQLA® (fruquintinib), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on November 8, 2023 for to treat refractory, metastatic colorectal cancer.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is FRUZAQLA® (fruquintinib) FDA approved?

Yes. The FDA approved FRUZAQLA® (fruquintinib), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on November 8, 2023 for to treat refractory, metastatic colorectal cancer. FDA novel drug approvals: "Fruzaqla | fruquintinib | 11/8/2023 | To treat refractory, metastatic colorectal cancerDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/fruquintinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/fruquintinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | FRUZAQLA® (fruquintinib) |
| Codes |  |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | To treat refractory, metastatic colorectal cancer |
| Modality | small_molecule |
| FDA designations | breakthrough, priority review |

## Timeline

### November 8, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat refractory, metastatic colorectal cancer.
- First seen 2025-03-19, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Fruzaqla | fruquintinib | 11/8/2023 | To treat refractory, metastatic colorectal cancerDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA217564 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20231108, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product FRUZAQLA (FRUQUINTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217564%22
- Press release filed with the SEC (EX-99) (accession 0001104659-25-025364): "Fruquintinib (FRUZAQLA® outside China) was approved by the FDA in November 2023 and by the European" https://www.sec.gov/Archives/edgar/data/1648257/000110465925025364/tm2423664d2_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/fruquintinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FRUZAQLA® (fruquintinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/fruquintinib

```bibtex
@misc{secapidev_pdufa_fruquintinib_20261116,
  title        = {FRUZAQLA® (fruquintinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/fruquintinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_fruquintinib_20261116","title":"FRUZAQLA® (fruquintinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/fruquintinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
